louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01119391: The Impact of Lifestyle Behaviors on In Vitro Fertilization (IVF) Outcome
Official title: The Impact of Lifestyle Behaviors on IVF Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Keywords: IVF
Lifestyle habits
Lead sponsor: Boston IVF
Sponsor class: OTHER
First posted: 2010-05-07
Enrollment: 118
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women about to undergo an in vitro fertilization cycle at Boston IVF

Brief summary: Many women undergoing in vitro fertilization (IVF) ask their doctor if there are any behaviors they should avoid, or any behaviors they should emphasize during their IVF cycle. This study examines the effects of health habits surrounding exercise, smoking, alcohol, sleep, caffeine, herbal medications, acupuncture, and diet on pregnancy rates during IVF cycles. The purpose of this study is to determine if lifestyle behaviors have a significant impact on pregnancy rates during treatment with IVF.

This is an observational study conducted at a private academically-affiliated infertility clinic and includes 118 women ages 44 and below scheduled to undergo IVF treatment. All subjects were asked to complete a health history survey at the time of enrollment and a daily survey during each day of their IVF cycle. The primary outcome is clinical pregnancy rate.


Eligibility criteria: Inclusion Criteria:

* Female Boston IVF infertility patient undergoing IVF treatment
* Age 18-44 years
* Able to read, understand and sign the informed consent in English
* Willing and able to comply with study requirements
* Must be well versed in using a personal computer and the internet and must have access to an internet-connected computer seven days per week

Primary outcomes:
measure: Clinical Pregnancy Rates
timeFrame: Approximately 28 days (1 IVF cycle)
Secondary outcomes:
Other outcomes:
Locations:
city: Waltham
country: United States
facility: Boston IVF
state: Massachusetts
Study officials:
affiliation: Boston IVF
name: Alice D Domar, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Domar AD, Conboy L, Denardo-Roney J, Rooney KL. Lifestyle behaviors in women undergoing in vitro fertilization: a prospective study. Fertil Steril. 2012 Mar;97(3):697-701.e1. doi: 10.1016/j.fertnstert.2011.12.012. Epub 2012 Jan 3.
Clinical trial NCT04230291: Hidradenitis Suppurativa Written Action Plan
Official title: Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Hidradenitis Suppurativa
Lead sponsor: University of Arizona
Sponsor class: OTHER
Collaborators: name: University of Arkansas
First posted: 2020-01-18
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is being conducted to evaluate if a written action plan for hidradenitis suppurativa (HS) will help patients with hidradenitis suppurativa gain a better understanding of the condition and how to manage the condition on a daily basis compared to a routine verbal consultation.


Eligibility criteria: Inclusion Criteria:

* Has a diagnosis of HS

Exclusion Criteria:

* Has been exposed to a written action plan for HS before

Primary outcomes:
measure: Visits to high-cost care settings
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona
state: Arizona
Study officials:
References:
Clinical trial NCT01427491: Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers
Official title: A Prospective, Multi-center, Randomized, Comparative Clinical Study to Compare Aquacel® Ag vs. Mepilex® Border Ag to Manage Bioburden in Leg Ulcers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Leg Ulcers
Lead sponsor: ConvaTec Inc.
Sponsor class: INDUSTRY
First posted: 2011-09-01
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the ability of Aquacel® Ag and Mepilex® Border Ag to manage bioburden in leg ulcers over a two week study period.


Eligibility criteria: Inclusion Criteria:

* Aged 18 years or over
* Willing and able to provide written informed consent
* Leg ulcer will be of size ranging between 10 cm2 - 40 cm2 with moderate or heavy exudate
* Leg ulcer will exhibit at least 2 of the 4 following clinical signs: pain between 2 dressing changes, peri-ulcer skin erythema, oedema, foul odour

Exclusion Criteria:

* Known skin sensitivity to any component of the products being tested
* Subjects who have had current local or systemic antibiotics and/or topical antimicrobials applied in the week prior to inclusion
* Depth of ulcer classified as superficial (not involving dermis) or deep (exposing muscle and tendon)
* Any other medical condition which, according to the investigator, justifies the subject's exclusion from the study
* Participated in a clinical study within the past 30 days

Primary outcomes:
measure: Microbial load reduction
timeFrame: Days 1 and 14
Secondary outcomes:
measure: clinical evolution of the wound (presence of each of the selected clinical signs)
timeFrame: Days 1, 3, 7, 14
measure: Occurrence of adverse events
timeFrame: Day 1-14
Other outcomes:
Locations:
city: Weaste
country: United Kingdom
facility: The Willows Centre for Health Care
state: Salford
city: Cardiff
country: United Kingdom
facility: Wound Healing Research Unit, Cardiff University
state: Wales
city: Upton
country: United Kingdom
facility: Arrowe Park Hospital
state: Wirral
Study officials:
affiliation: Cardiff University
name: Keith Harding
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01557491: Hair Regrowth After Bicoronal Incision
Official title: A Randomized Blinded Comparison of Hair Growth Following Either Bevelled or Standard Bi-coronal Scalp Incisions.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alopecia
Keywords: Alopecia
Coronal Incision
Scar Quality
Lead sponsor: Sunnybrook Health Sciences Centre
Sponsor class: OTHER
First posted: 2012-03-19
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Loss of hair growth potential in long surgical scalp incisions can become obvious to the patient and others, given hair's tendency to part along the resulting scar. Bevelling incisions perpendicular to the hair follicle angle may increase hair growth through the scar. However, many factors may be confounders such as wound tension and cauterizing the incision. This study will investigate the effect a bevelled incision has on hair growth preservation compared to a standard incision that incises the skin perpendicular to its surface irrespective of hair follicle angles. Following informed voluntary consent, subjects who require bi-coronal scalp incisions as part of a surgical plan will be enrolled. The right side of this bilateral incision will be randomized to receive either a bevelled or a standard incision and the left side will receive the opposite type. During routine surgical follow-up the hair growth within the scar of the two sides will be recorded for comparison and it is our hypothesis that the side with the bevelled incision will have more hair within the scar.


Eligibility criteria: Inclusion Criteria:

* Bicoronal Incision required as part of surgical plan
* Incision within hair-bearing scalp

Exclusion Criteria:

* Previous Bicoronal Incision
* Unfit for Surgery
* Unable to provide informed consent
* Unable to comply with followup
* Preexisting alopecia of scalp
* Cutaneous malignancy of scalp

Primary outcomes:
measure: Hair Regrowth Within the Scar
timeFrame: 12 months
Secondary outcomes:
measure: Scar Characteristics
timeFrame: 1 year post surgery
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Sunnybrook Health Sciences Centre
state: Ontario
Study officials:
affiliation: University of Toronto Plastic and Reconstructive Surgery
name: Mathew A Plant, MD
role: STUDY_DIRECTOR
References:
citation: Camirand A, Doucet J. A comparison between parallel hairline incisions and perpendicular incisions when performing a face lift. Plast Reconstr Surg. 1997 Jan;99(1):10-5. doi: 10.1097/00006534-199701000-00002.
citation: Sullivan T, Smith J, Kermode J, McIver E, Courtemanche DJ. Rating the burn scar. J Burn Care Rehabil. 1990 May-Jun;11(3):256-60. doi: 10.1097/00004630-199005000-00014.
Clinical trial NCT01298791: The Impact Of Physician Communication On Family Inpatient Experience
Official title: The Impact Of Physician Communication On Family Inpatient Experience
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Parental/Patient Satisfaction
Lead sponsor: Boston Medical Center
Sponsor class: OTHER
First posted: 2011-02-18
Enrollment: 0
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Patient satisfaction is affected by physician communication styles and communication at the bedside. The investigators are conducting a randomized controlled trial involving both providers and families to determine if providers sitting down while talking with families, will improve one aspect of quality care delivered during an inpatient stay as measured by patient/family satisfaction. The investigators will additionally study the affects of the intervention on the following outcomes: family assessment of provider communication, readmission rates, and length of stay.


Eligibility criteria: Inclusion Criteria:

* Providers: all attendings, residents, and medical students involved in the care of patients on the pediatric inpatient wards during the study period.
* Families (Parents or legal guardians and children):
* (1) inpatient admissions to the pediatrics medical service at Boston Medical Center
* (2) whose parents or guardian have agreed to participate in family centered walk rounds
* (3) patients age 17 or younger who have family members present at the bedside each morning of hospitalization
* (4) English speaking.

Exclusion Criteria:

* (1) All patients/families that as part of admission justification involves social assessment and concern by the patient care team, including patients with neonatal abstinence syndrome, child maltreatment, and concern for neglect.
* (2) All patients transferred to or from PICU as part of their inpatient care
* (3) All patients transferred from an outside institution to the inpatient ward for further care secondary to progression of disease.

Primary outcomes:
measure: Patient/family satisfaction
timeFrame: 4mo
measure: Patient/family Satisfaction
timeFrame: 4 mo
measure: Patient/family satisfaction
timeFrame: 4 months
Secondary outcomes:
measure: Length of stay
timeFrame: 4 months
measure: Readmission rate
timeFrame: 5 mo
measure: Family discharge preparedness
timeFrame: 4 mo
measure: Follow-up appointment attendance
timeFrame: 5 mo
measure: Family assessment of doctor-patient communication skills
timeFrame: 4 mo
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
Study officials:
affiliation: Boston Medical Center
name: Michael Silverstein, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00772291: Chronic Pain Management After Herniorraphy
Official title: Chronic Pain Management After Herniorraphy:Pregabalin vs Placebo. A Double-blinded Randomised Controlled Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Pain
Keywords: inguinal
hernia
chronic
pain
pregabalin
chronic pain after inguinal herniorraphy
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
First posted: 2008-10-15
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Nowadays, chronic pain mainly as a result of iatrogenic nerve damage is generally considered as the most frequent complication after inguinal hernia surgery. The primary objective of this randomised double-blind placebo-controlled trial is to investigate whether pregabalin reduces pain in patients with chronic pain of neuropathic origin after herniorraphy.


Eligibility criteria: Inclusion Criteria:

1. History of unilateral inguinal herniotomy
2. Establishment of neuropathic character of chronic pain by means the LANSS painscore and DN4 score
3. Abnormal sensitivity (allodynia, dysesthesia, hypoesthesia or dysesthesia) in or around the incisional area
4. Duration pain ≥ 3 months
5. Medial or lateral inguinal hernia
6. Age ≥ 18 years
7. VAS score ≥ 40 mm on Vas scale on which they indicate 'how unpleasant or disturbing the worst pain was that they had today'
8. Grade III or IV pain and discomfort on the 4-point pain and discomfort scale
9. Informed consent (addendum V)

Exclusion Criteria:

1. Participation in another trial
2. Age \< 18 years
3. Cognitive disfunction
4. Patient is unable to speak Dutch
5. Hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption
6. Patient classified as American Society of Anaesthesiologist Class 4
7. Renal impairment

Primary outcomes:
measure: pain
timeFrame: 8 weeks
Secondary outcomes:
measure: quantitative sensory testing (QST) accuracy in testing the inguinal region
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus Medical Center
Study officials:
affiliation: Erasmus Medical Center
name: J.F. Lange, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05795491: Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis
Official title: Effect of Blue Light Emitting Diode Therapy on Recurrent Vulvovaginal Candidiasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Recurrent Vulvovaginal Candidiasis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-04-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: With the knowledge that VVC is an infectious disease of the genitourinary tract that is common in women of reproductive age, and because of the shortage of non-drug therapies for this condition, this study will aim to evaluate the effect of ultraviolet A/blue LED with a wavelength of 401 ± 5 nm in patients with a clinical manifestation of candidiasis and its ability to prevent recurrence.

Detailed description: Vulvovaginal candidiasis (VVC) is an infection of the vulva and vagina caused by the abnormal growth of several Candida species. This pathology is one of the most common diagnoses in gynecological practice and the second most common genital infection. Studies have shown that 15 to 25% of adult women present with fungal colonization despite being asymptomatic and that 75% of them will develop the disease at some point in their lives.

The treatment of VVC involves the use of antifungal agents, either orally or topically, which resolves 80 to 90% of the cases. However, the use of these agents can lead to the development of adverse reactions such as dysuria, pruritus, and gastrointestinal disorders.

Accordingly, a hypothesis arises that the blue/violet light- emitting diode (LED) may be an alternative treatment for women with VVC because of its antimicrobial effect that has been proven by several studies. Moreover, it is considered a safe, non-invasive, painless, and non-toxic technique for use in several types of tissue.

Eligibility criteria: Inclusion Criteria:

subject selection will be according to the following criteria:

1. Age will range between 18- 50 years.
2. All patients will be confirmed by culture and examination of fresh vaginal samples, to have VVC.
3. All patients who will be enrolled to the study will have their informed consent.

Exclusion Criteria:

The participants will be excluded if they meet one of the following criteria:

1. Individuals on any other antifungal drugs.
2. Individuals with cardiopulmonary conditions.
3. Individuals undergoing another radiation therapy.
4. Sensory impairment

Primary outcomes:
measure: Vaginal swab culture .
timeFrame: 2 months
Secondary outcomes:
measure: Litmus Paper
timeFrame: 2 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of physical therapy, Cairo University
Study officials:
affiliation: Professor of physical Therapy, Faculty of Physical therapy, Cairo University
name: Soheir El-kosery, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04019691: Comparing the Visual Outcome, Visual Quality, and Satisfaction Among Three Types of Multi-focal Intraocular Lenses
Official title: Comparing the Visual Outcome, Visual Quality, and Satisfaction Among Three Types of Multi-focal Intraocular Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Keywords: multifocal intraocular lens
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2019-07-15
Enrollment: 60
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators are going to Investigate the comparative efficacy of the patients who underwent cataract surgery with three different multifocal IOLs.

Detailed description: Going to analyze the clinical results of 60 patients who underwent bilateral cataract surgery and multifocal IOL implantation. The patients were divided into the following three groups: Mix-and-Match, EDOF, and Trifocal. The clinical assessments included uncorrected near, intermediate, distance and best corrected distance visual acuity, defocus curves, contrast sensitivity, and reading speed. Patient satisfaction was evaluated by questionnaire. All outcomes were compared among the three groups.

Eligibility criteria: Inclusion Criteria:

* Patients with bilateral senile cataracts and the desire to be spectacle-free for all distances

Exclusion Criteria:

* Patients younger than 21 years, had corneal astigmatism \>1.00 D, previous ocular surgery or trauma, or ocular disease other than cataracts

Primary outcomes:
measure: Postoperative uncorrected near, intermediate, and far visual acuity.
timeFrame: At 1month and 3months after surgery
measure: Postoperative contrast sensitivity in the three groups.
timeFrame: Postoperative 3 months
measure: Postoperative satisfaction questionnaire.
timeFrame: Postoperative 3 months
Secondary outcomes:
measure: Postoperative refractive outcome
timeFrame: Postoperative 3 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
citation: Paik DW, Park JS, Yang CM, Lim DH, Chung TY. Comparing the visual outcome, visual quality, and satisfaction among three types of multi-focal intraocular lenses. Sci Rep. 2020 Sep 9;10(1):14832. doi: 10.1038/s41598-020-69318-y.
Clinical trial NCT02678091: Ultrasound Exam With Doppler for the Etiological Diagnosis of Orbital Masses (PUCE)
Official title: Contribution of the Quantitative Analysis of the Ultrasound Exam With Doppler for the Etiological Diagnosis of Orbital Masses (PUCE)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tumor of the Orbit
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-02-09
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Orbital masses develop at the expense of the orbital structures lacrimal glands, oculomotor muscles, optic nerve, meningeal spaces, peripheral nerves, bone wall, orbital fat, lymphoid structures or vascular structures. These masses can be tumors, benign or malignant, or pseudotumor, mainly represented by specific or non-specific orbital inflammation.

Pathology is of considerable importance for the diagnosis and the treatment of those masses. However, biopsy or surgical resection of the orbital masses is sometimes difficult and dangerous outside expert centers.

The identification of a non-invasive technique for distinguishing tumors from pseudotumors, thus avoid in some cases a biopsy, would be a major contribution for the patients.

Quantitative analysis of the ultrasound exam with doppler of those masses could identify diagnostic criteria, especially for the lacrimal gland, easily explorable.


Eligibility criteria: Inclusion Criteria:

* patient aged 18 years or more
* with an orbital mass for which a biopsy and/or a surgical removal is planned
* before surgery or biopsy

Exclusion Criteria:

* pregnancy
* breast feeding
* patient under a legal protection procedure
* patient denying to participate to the study
* lack of affiliation to a social security system

Primary outcomes:
measure: Sensitivity, expressed as a percentage, of the ultrasound exam with Doppler, the pathological exam being the gold standard
timeFrame: One month
measure: Specificity, expressed as a percentage, of the ultrasound exam with Doppler, the pathological exam being the gold standard
timeFrame: One month
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation ophtalmique Adolphe de Rothschild
Study officials:
References: